The firms note that Colgate has a number of initiatives driving improved results and expect earnings growth to continue to outpace the group.  Despite a recent step back, the firms expect reinvestment into Ajax and Palmolive to continue at a robust pace, driving above-average local currency sales growth.  Colgate has a number of initiatives driving improved results, and they expect earnings growth to continue to outpace the group. The neutral firms are primarily concerned about the intense competitive environment in several developing markets, including China, Russia, India, Brazil, and Mexico, with major competitors like Procter & Gamble, Unilever, and GlaxoSmithKline also stepping up in product introductions and investment spending. Most of the firms based their valuation on forward EPS multiples and DCF analysis.

The firms believe that the most significant near-term risk to CL's earnings growth is the competitive environment as several of CL's competitors has made new product introductions and increased investment spending.  Over the long term, another risk to consider for CL is foreign currency translation.